Correction

Correction: Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway

The *PLOS ONE* Staff

The following information is missing from the Funding section: Infrastructure support: RCMI: G12RR03051, G12MD007600. The correct funding information is as follows: Funding: This project was supported partially by the NIH/NCI (1K22CA166226-01A1) to PEVM, institutional seed funds from the University of Puerto Rico. Comprehensive Cancer Center (PEVM), National Institute of Health, and Minority Biomedical Research Support (MBRS) RISE Grant Number R25-GM061838 (IEV). Infrastructure support: RCMI: G12RR03051, G12MD007600. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Reference

1. Echevarría-Vargas IM, Valiyeva F, Vivas-Mejía PE (2014) Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway. *PLoS ONE* 9(5): e97094. doi:10.1371/journal.pone.0097094

Citation: The *PLOS ONE* Staff (2014) Correction: Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway. *PLoS ONE* 9(12): e116447. doi:10.1371/journal.pone.0116447

Published: December 26, 2014

Copyright: © 2014 The *PLOS ONE* Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.